Cargando…

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, Ross L., Kavanagh, Kimberley, Pan, Jiafeng, Love, John, Cuschieri, Kate, Robertson, Chris, Ahmed, Syed, Palmer, Timothy, Pollock, Kevin G.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696690/
https://www.ncbi.nlm.nih.gov/pubmed/26692336
http://dx.doi.org/10.3201/eid2201.150736
_version_ 1782407815613120512
author Cameron, Ross L.
Kavanagh, Kimberley
Pan, Jiafeng
Love, John
Cuschieri, Kate
Robertson, Chris
Ahmed, Syed
Palmer, Timothy
Pollock, Kevin G.J.
author_facet Cameron, Ross L.
Kavanagh, Kimberley
Pan, Jiafeng
Love, John
Cuschieri, Kate
Robertson, Chris
Ahmed, Syed
Palmer, Timothy
Pollock, Kevin G.J.
author_sort Cameron, Ross L.
collection PubMed
description In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level.
format Online
Article
Text
id pubmed-4696690
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-46966902016-01-05 Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013 Cameron, Ross L. Kavanagh, Kimberley Pan, Jiafeng Love, John Cuschieri, Kate Robertson, Chris Ahmed, Syed Palmer, Timothy Pollock, Kevin G.J. Emerg Infect Dis Research In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level. Centers for Disease Control and Prevention 2016-01 /pmc/articles/PMC4696690/ /pubmed/26692336 http://dx.doi.org/10.3201/eid2201.150736 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Cameron, Ross L.
Kavanagh, Kimberley
Pan, Jiafeng
Love, John
Cuschieri, Kate
Robertson, Chris
Ahmed, Syed
Palmer, Timothy
Pollock, Kevin G.J.
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
title Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
title_full Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
title_fullStr Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
title_full_unstemmed Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
title_short Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
title_sort human papillomavirus prevalence and herd immunity after introduction of vaccination program, scotland, 2009–2013
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696690/
https://www.ncbi.nlm.nih.gov/pubmed/26692336
http://dx.doi.org/10.3201/eid2201.150736
work_keys_str_mv AT cameronrossl humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT kavanaghkimberley humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT panjiafeng humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT lovejohn humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT cuschierikate humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT robertsonchris humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT ahmedsyed humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT palmertimothy humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013
AT pollockkevingj humanpapillomavirusprevalenceandherdimmunityafterintroductionofvaccinationprogramscotland20092013